Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 26;5(2):607-612.
doi: 10.1182/bloodadvances.2020001792.

BiTEs better than CAR T cells

Marion Subklewe

BiTEs better than CAR T cells

Marion Subklewe. Blood Adv. .

Abstract

This article has a companion Point by Molina and Shah.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: M.S. receives industry research support from Amgen, Gilead, Miltenyi, Morphosys, Roche, and Seattle Genetics; is on the advisory boards of Amgen, Celgene, Gilead, Janssen, Novartis, Pfizer, BMS, and Seattle Genetics; and is on the speaker’s bureau at Amgen, Celgene, Gilead, Janssen, Novartis, and Pfizer.

Comment in

References

    1. Kontermann RE, Brinkmann U. Bispecific antibodies [published correction appears in Drug Discov Today 2019:24(7):1422]. Drug Discov Today. 2015;20(7):838-847. - PubMed
    1. Goebeler M-E, Bargou RC. T cell-engaging therapies - BiTEs and beyond. Nat Rev Clin Oncol. 2020;17(7):418-434. - PubMed
    1. June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379(1):64-73. - PMC - PubMed
    1. Kantarjian H, Stein A, Gökbuget N, et al. . Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836-847. - PMC - PubMed
    1. Gökbuget N, Dombret H, Bonifacio M, et al. . Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia [published correction appears in Blood. 2019;133(24):2625]. Blood. 2018;131(14):1522-1531. - PMC - PubMed

Publication types